0
Articles |

A Comparison of Two Long-Acting Vasoselective Calcium Antagonists in Pulmonary Hypertension Secondary to COPD

Dimitar Sajkov; Tingting Wang; Peter A. Frith; Alexandra J. Bune; John A. Alpers; R. Douglas McEvoy
Author and Funding Information

Affiliations: From the Department of Respiratory Medicine, Repatriation General Hospital, Flinders University Medical Centre, Adelaide, South Australia,  From the Department of Cardiology, Repatriation General Hospital, Flinders University Medical Centre, Adelaide, South Australia,  From the Department of Respiratory Medicine, Flinders University Medical Centre, Adelaide, South Australia

Affiliations: From the Department of Respiratory Medicine, Repatriation General Hospital, Flinders University Medical Centre, Adelaide, South Australia,  From the Department of Cardiology, Repatriation General Hospital, Flinders University Medical Centre, Adelaide, South Australia,  From the Department of Respiratory Medicine, Flinders University Medical Centre, Adelaide, South Australia

Affiliations: From the Department of Respiratory Medicine, Repatriation General Hospital, Flinders University Medical Centre, Adelaide, South Australia,  From the Department of Cardiology, Repatriation General Hospital, Flinders University Medical Centre, Adelaide, South Australia,  From the Department of Respiratory Medicine, Flinders University Medical Centre, Adelaide, South Australia


1997 by the American College of Chest Physicians


Chest. 1997;111(6):1622-1630. doi:10.1378/chest.111.6.1622
Text Size: A A A
Published online

Abstract

Study objectives and patients: Pulmonary hypertension (PH) is common in COPD and may predict mortality in this disorder. We have compared the pulmonary vasodilator effects, dose-response characteristics, and tolerability of two calcium channel blockers, amlodipine and extended-release (ER) felodipine, in 10 patients (seven men, age 68±4.8 [SD] years) with clinically stable COPD and PH.

Design: Drugs were given in equal single daily oral doses (2.5, 5, and 10 mg), increasing weekly for 3 weeks, in a randomized investigator-blinded crossover manner with a 1-week wash-out period between the two treatments.

Measurements: Doppler measurements of pulmonary hemodynamics were made on the seventh day of treatment at each drug dose. Lung function, arterial blood gases, and adverse events were also monitored weekly.

Results: A dose-dependent decline of pulmonary artery pressure (PAP) was observed with each drug. A dose of 2.5 mg produced a significant decrease in PAP compared with baseline (20% amlodipine, 17% felodipine ER). Additional decreases in PAP were observed at 5 mg and 10 mg that were similar for both drugs, but did not reach statistical significance compared with 2.5 mg. There was a dose-related decrease in pulmonary vascular resistance and increase in oxygen delivery with amlodipine and felodipine ER. Lung function and blood gas values were stable throughout. Side effects (headache and ankle edema) were less frequent during amlodipine treatment (p<0.05).

Conclusions: Both amlodipine and felodipine ER, given as a single daily oral dose of ≥2.5 mg, are effective pulmonary vasodilators in COPD patients with PH. Their dose-response characteristics are similar, but amlodipine treatment was associated with fewer side effects.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543